Tracey O'Connor

Medical Oncology

Specializing In:

Breast cancer

Special Interests:

Novel treatments for breast cancer Psychological impact of breast cancer Supportive care therapies for patients with advanced disease Survivorship issues and breast cancer

About Tracey O'Connor

Positions

Roswell Park Comprehensive Cancer Center

Associate Professor, Department of Medicine

Jacobs School of Medicine and Biomedical Sciences, University at Buffalo

Associate Professor of Clinical Medicine

Background

Education and Training:

MD - School of Medicine and Biomedical Sciences, State University of New York at Buffalo
BS - Northwestern University, Evanston, IL

Residency:

Strong Memorial Hospital, University of Rochester Medical Center, Rochester, NY

Fellowship:

Roswell Park Cancer Institute, Buffalo, NY

Board Certification:

Internal Medicine, American Board of Internal Medicine
Medical Oncology, American Board of Internal Medicine

Clinical Trials

Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Learn More

Exercise and Nutrition Education in Improving Physical Function and Quality of Life in Older Breast Cancer Survivors

Learn More

Exercise in Improving Health and Quality of Life in Breast Cancer Survivors

Learn More

Featured on Cancer Talk

Publications

Full Publications list on PubMed

Kossoff E, Ngamphaiboon N, 21214. Balancing the efficacy and safety of ixabepilone: Optimizing treatment in metastatic breast cancer. Community oncology 2012; 97:222-228
O'Connor TL, Edge SB, Kossoff EB, Groman A, Wilding GE, Ademuyiwa FO, Levine EG, Watroba N, Ngamphaiboon N. Factors affecting the delivery of adjuvant/neoadjuvant chemotherapy in older women with breast cancer. Journal of geriatric oncology 2012; 34:320-328
Ngamphaiboon N, O'Connor TL, Advani PP, Levine EG, Kossoff EB. Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis. Medical oncology (Northwood, London, England) 2012; 293:1495-1501
Ademuyiwa FO, Bshara W, Attwood K, Morrison C, 4533, Ambrosone CB, O'Connor TL, Levine EG, Miliotto A, Ritter E, Ritter G, Gnjatic S, Odunsi K. NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer. PloS one 2012; 76:e38783
Hurria A, Browner IS, Cohen HJ, Denlinger CS, DeShazo M, Extermann M, Ganti AKP, Holland JC, Holmes HM, Karlekar MB, Keating NL, McKoy J, Medeiros BC, Mrozek E, O'Connor T, Petersdorf SH, Rugo HS, Silliman RA, Tew WP, Walter LC, Weir III AB, Wildes T. Senior adult oncology. Journal of the National Comprehensive Cancer Network : JNCCN 2012; 102:162-209
Waldrop DP, O'Connor TL, Trabold N. "Waiting for the other shoe to drop": Distress and coping during and after treatment for breast cancer. Journal of psychosocial oncology 2011; 294:450-473
Ademuyiwa FO, Groman A, O'Connor T, Ambrosone C, Watroba N, Edge SB. Impact of body mass index on clinical outcomes in triple-negative breast cancer. Cancer 2011; 11718:4132-4140
Ngamphaiboon N, Frustino JL, Kossoff EB, Sullivan MA, O'Connor TL. Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab. Clinical breast cancer 2011; 114:252-257
Yao S, O'Connor TL, Edge SB, Kulkarni S, Hwang H, McCann SE, Hong C-C, Davis W, Nesline MK, Trump DL, Johnson CS, Millen AE, Sucheston LE, Ambrosone CB. Pretreatment serum concentrations of 25-hydroxyvitamin d and breast cancer prognostic characteristics: a case-control and a case-series study.PloS one 2011; 62:e17251
Bush E, Lamonica D, O'Connor T. Sarcoidosis mimicking metastatic breast cancer. Breast journal 2011;175:533-535
Ademuyiwa FO, Miller A, O'Connor T, Edge SB, Thorat MA, Sledge GW, Levine E, Badve S. The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. Breast cancer research and treatment 2011; 1263:797-802
Kossoff EB, Ngamphaiboon N, Laudico TJ, O'Connor TL. Weekly ixabepilone administration in heavily pretreated metastatic breast cancer patients. Medical oncology (Northwood, London, England) 2011;28Suppl. 1:S115-S120
Berger AM, Kaldor P, Ligibel JA, Murphy BA, O'Connor T, Pirl WF, Rodler E, Rugo HS, Thomas J, Jacobsen PB, Escalante CP, Abernethy AP, Atkinson A, Barsevick AM, Breitbart WS, Cella D, Cimprich B, Cleeland C, Eisenberger MA, Wagner LI. Cancer-related fatigue. Journal of the National Comprehensive Cancer Network : JNCCN 2010; 88:904-931
O'Connor TL, Kossoff E. Delayed seizure associated with paclitaxel-Cremophor el in a patient with early-stage breast cancer. Pharmacotherapy 2009; 298:993-996
O'connor T, Rustum Y, Levine E, Creaven P. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer. Cancer chemotherapy and pharmacology 2008; 611:125-131
Mock V, Kaldor P, O'Connor T, Otis-Green SA, Piper BF, Pirl WF, Rugo HS, Sabbatini P, Stewart FM, Jacobsen PB, Hinds P, Escalante CP, Abernethy AP, Atkinson A, Barsevick AM, Berger AM, Cella D, Cimprich B, Cleeland C, Eisenberger MA, Wagner LI. Cancer-related fatigue. Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN 2007; 510:1054-1078

Request an Appointment

Make an appointment by calling 1-800-ROSWELL (1-800-767-9355)

Make an Appointment

See what others are saying about Tracey O'Connor, MD, and leave your own review.

Reputation Reviews

Leave a Review